Drug Target for Cancer: ICOS Ligand

Drug Targets for Cancer: ICOS Ligand and Cancer

ICOS is related to the CD28 superfamily and is highly expressed on activated T cells as well as regulatory T cells and is crucial for the survival and function of T cells, Th2 cell differentiation and for lung inflammatory responses. Binding ICOS to ICOS-Ligand activates a cascade of intracellular signaling molecules that prevent apoptosis and lead to the production of cytokines such as IL-4 and IL-13 . To date, ICOS Ligand has been reported to be expressed by B cells, non-lymphoid and lung epithelial cells but not by T cells or innate lymphoid cells and is down-regulated upon binding to ICOS as an immunoregulatory mechanism. The functional requirement of ICOS for the function and survival of ILC2 remains to be elucidated.

Drug Targets for Cancer: ICOS Ligand related Products

Drug Targets for Cancer: ICOS Ligand Related Reference

Maazi H, Patel N, Sankaranarayanan I, et al. ICOS:ICOS-Ligand interaction is required for type 2 innate lymphoid cell function, homeostasis and induction of airway hyperreactivity. Immunity. 2015;42(3):538-551.

Drug Targets for Cancer: ICOS Ligand Related Information